Results 91 to 100 of about 23,209 (275)

Donepezil‐Induced Severe Anorexia and T‐Wave Inversion in Early‐Onset Alzheimer's Disease: A Case Report

Clinical Case Reports, Volume 14, Issue 1, January 2026.
ABSTRACT Donepezil hydrochloride, used to treat Alzheimer's disease, is typically initiated at a low dose and titrated to minimize gastrointestinal side effects. Despite its favorable safety profile, the patient developed severe anorexia, dehydration, and electrocardiographic abnormalities.
Nobuyuki Takahashi, Takeshi Kuroda, Takashi Yoshioka, Hidetomo Murakami, Hironori Tanaka   +4 more
wiley   +1 more source

Donepezil and related cholinesterase inhibitors as mood and behavioral controlling agents. [PDF]

, 2000
Acetylcholinesterase inhibitors (ChEIs) enhance neuronal transmission by increasing the availability of acetylcholine in muscarinic and nicotinic receptors.
A Grob, BJ Carroll, BJ Steinberg, CH Dyck van, D Kaufer, DE Giles, DJ Safer, DS Geldmacher, DS Janowsky, DS Janowsky, DS Janowsky, DS Janowsky, DW Rowntree, EF Willoughby, JC Morris, JL Cummings, JL Cummings, JM Cooney, JM Cooney, KL Davis, KL Lanctot, LJ Thal, M Rosler, MA Raskind, MA Raskind, MA Raskind, MB Bowers, MF Weiner, MS Mega, MS Mega, N Sitaram, PJ Goodnick, PN Tariot, PS Kishnani, RE Becker, RT Rubin, SC Risch, SP Hoopes, SP Wengel, SS Leong, T Burt, Tal Burt, WJ Burke, YM Greene   +43 more
core   +1 more source

Long‐Term Effect of Acetylcholinesterase Inhibitors on Behavioral and Psychological Symptoms of Dementia

International Journal of Geriatric Psychiatry, Volume 41, Issue 1, January 2026.
ABSTRACT Objective Behavioral and psychological symptoms of dementia (BPSD) are critical aspects of the clinical presentation of dementia. There is no universally accepted approach for the managment of BPSD, currently based first on a non‐pharmacological and subsequently on a pharmacological approach.
Giovanni Zuliani, Francesca Boscolo Bragadin, Tommaso Romagnoli, Michele Polastri, Carlo Cervellati, Francesco di Paola Dario, Gloria Brombo, Marco Zuin   +7 more
wiley   +1 more source

Exploring Autophagy Inducing Molecules: Targeting Diverse Pathways in Alzheimer's Disease Management

Medicinal Research Reviews, Volume 46, Issue 1, Page 272-298, January 2026.
ABSTRACT Neurodegenerative disorders, including Alzheimer's disease (AD), impose a significant burden on society due to their progressive nature and the associated healthcare costs. Autophagy, a vital cellular degradation process, has emerged as a promising therapeutic target in these disorders.
Baljinder Singh, Shubham Mahajan, Sadikalmahdi Abdella, Rehan Khan, Sanjay Garg   +4 more
wiley   +1 more source

Bioactive Phenolic Compounds from Thapsia garganica L. Different Parts: HPLC‐DAD Profiling,Cholinesterase Inhibition, and Antioxidant Potential

ChemistrySelect, Volume 11, Issue 1, 8 January 2026.
ABSTRACT This study investigates the biological properties of methanolic and petroleum ether (PE) extracts from the roots and flowers of Thapsia garganica L., providing new insights into its potential medicinal uses. Although T. garganica has a long history in traditional medicine, the anticholinesterase and tyrosinase‐inhibiting activities of this ...
Rania Arabi, Meriem Chafaa, Dilaycan Çam, Cansel Çakir, Zohra Arabi, Leila Soudani, Mehmet Öztürk, Tarek H. Taha, Sulaiman A. Alsalamah, Takfarinas Idres, Stefania Garzoli, Hamdi Bendif   +11 more
wiley   +1 more source

Methylphenidate and galantamine in patients with vascular cognitive impairment–the proof-of-principle study STREAM-VCI

Alzheimer's Research & Therapy, 2020
To date, no symptomatic treatment is available for patients with vascular cognitive impairment (VCI). In the proof-of-principle study Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI), we investigated whether a single dose of a ...
J. Leijenaar, G. Groeneveld, E. Klaassen, A. Leeuwis, P. Scheltens, H. Weinstein, J. V. van Gerven, F. Barkhof, W. M. van der Flier, N. Prins   +9 more
semanticscholar   +1 more source

Enhanced parasympathetic cholinergic activity with galantamine inhibited lipid-induced oxidative stress in obese African Americans

Molecular Medicine, 2022
Background African Americans (AAs) are disproportionately affected by cardiovascular disease (CVD), they are 20% more likely to die from CVD than whites, chronic exposure to inflammation and oxidative stress contributes to CVD.
Dena Parsa, Luul A. Aden, Ashley Pitzer, Tan Ding, Chang Yu, Andre Diedrich, Ginger L. Milne, Annet Kirabo, Cyndya A. Shibao   +8 more
doaj   +1 more source

Blood biomarkers for Alzheimer's disease are correlated with measures of agitation and cognition in a randomized trial assessing the effects of escitalopram on agitation

Alzheimer's &Dementia: Translational Research &Clinical Interventions, Volume 12, Issue 1, January/March 2026.
Abstract INTRODUCTION Escitalopram for Agitation in Alzheimer's Disease (S‐CitAD) is a National Institutes of Health–funded randomized controlled trial that randomized 173 participants with clinically diagnosed Alzheimer's disease (AD) and agitation to escitalopram or placebo for 12 weeks, assessing efficacy and safety.
Maansi Barnwal, Sheriza Baksh, Zahinoor Ismail, David M. Shade, Abhay Moghekar, Sara G. Ho, Paul B. Rosenberg, Anton P. Porsteinsson, Constantine G. Lyketsos, for the S‐CitAD Research Group   +9 more
wiley   +1 more source

Potential benefits of phytochemicals against Alzheimer's disease [PDF]

, 2017
Our current therapeutic drugs for Alzheimer's disease are predominantly derived from the alkaloid class of plant phytochemicals. These drugs, such as galantamine and rivastigmine, attenuate the decline in the cholinergic system but, as the alkaloids ...
Wightman, Emma
core   +1 more source

Effect of Early‐Onset Dementia on Job Loss in Japan: A Matched Cohort Database Study Using Health Insurance Claims Data

Psychogeriatrics, Volume 26, Issue 1, January 2026.
ABSTRACT Objective To assess the rate of job loss amongst primary insured participants diagnosed with early‐onset dementia (EOD) and to investigate the association between patients' background factors and job loss. Additionally, we evaluated the job loss rates amongst primary insured participants whose spouses were diagnosed with EOD.
Kenta Sumitomo, Yoichi Higashibeppu, Masataka Tajima, Hitoshi Sato, Erika Sugiyama   +4 more
wiley   +1 more source